C4 Therapeutics Files 8-K on Operations and Finance

Ticker: CCCC · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1662579

C4 Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyC4 Therapeutics, Inc. (CCCC)
Form Type8-K
Filed DateJan 14, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-k, financial-condition, operations

TL;DR

C4 Therapeutics dropped an 8-K updating investors on its financials and operations.

AI Summary

C4 Therapeutics, Inc. filed an 8-K on January 14, 2025, reporting on its results of operations and financial condition, as well as a Regulation FD Disclosure. The filing does not contain specific financial figures or event details within the provided text, but indicates a report on the company's operational and financial status.

Why It Matters

This filing provides an update on C4 Therapeutics' financial health and operational status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification without specific negative or positive disclosures that would indicate a high risk.

Key Players & Entities

  • C4 Therapeutics, Inc. (company) — Registrant
  • January 14, 2025 (date) — Date of earliest event reported
  • 490 Arsenal Way, Suite 120 (address) — Principal Executive Offices
  • Watertown, MA 02472 (address) — Principal Executive Offices

FAQ

What specific events or financial results are being reported in this 8-K filing?

The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' as of January 14, 2025, but the specific details of these results are not provided in the excerpt.

What is the primary purpose of this 8-K filing for C4 Therapeutics, Inc.?

The primary purpose is to report on the company's results of operations and financial condition, and to make a Regulation FD Disclosure.

When was this 8-K filing submitted or effective?

The filing was made as of January 14, 2025.

Where are C4 Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 490 Arsenal Way, Suite 120, Watertown, MA 02472.

What is the SIC code for C4 Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for C4 Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 920 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2025-01-14 07:09:21

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 14, 2025, C4 Therapeutics, Inc. (the " Company ") disclosed that its unaudited cash, cash equivalents, and marketable securities as of December 31, 2024, will enable the Company to fund its operating plan into 2027. The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024 and its results of operations for the three months and year ended December 31, 2024. The audit of the Company's consolidated financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information set forth above. The information contained in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 14, 2025, the Company issued a press release announcing its key milestones anticipated for 2025 and also that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST), with a live webcast that will be available for viewing under "Events & Presentations" on the Investors page of the Company's website at www.c4therapeutics.com . A replay of the webcast will be made available on the Company website for at least two weeks. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K . On January 14, 2025, the Company also posted a corporate presentation on its website at https://ir.c4therapeutics.com/events-presentations . A copy of the presentation is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Press release issued January 14, 2025 99 Corporate presentation of the Company dated January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: January 14, 2025 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.